Aesthetic Medicine Symposium - November 14-16 in Scottsdale, AZ!Register Now
Celebrating 20 Years of Excellence in Botox®, Aesthetic Medicine & Medical Weight Management Training & Certification
Aesthetic Medicine Symposium — Nov 14–16, Scottsdale, AZ Register Now →
Empowering Medical Aesthetic Clinics, Practitioners, and Patients
Botox® Danger Zones: Why Expertise Matters
Last updated: September 2026
Botox® danger zones are not really places on the face. They are muscles you did not intend to treat. Botulinum toxin does not stay perfectly where the needle put it — it diffuses a short distance through tissue, and if a neighbouring muscle is close enough and the dose is large enough, that muscle relaxes too. A danger zone is simply an area where the muscle next door does a job the patient very much wants it to keep doing: holding the eyelid open, lifting the brow, sealing the lips, swallowing.
That is why the FDA prescribing information for BOTOX® Cosmetic does not say “avoid the eye area.” It gives injectors measurements: at least 1 cm above the bony supraorbital ridge, no closer than 1 cm above the central eyebrow, at least 2 cm above the eyebrow on the forehead, at least 1 cm below the jawline in the neck. Those numbers are the difference between a good result and a droopy eyelid after Botox® that the patient lives with for weeks.
This guide walks the face zone by zone: which muscle is genuinely at risk in each one, what goes wrong when toxin reaches it, what the label says to do about it, and how often it actually happens according to the clinical trial data. It also covers the two danger zones that are not anatomical at all — the wrong patient, and the wrong product.
Key Takeaways
Danger zones are defined by muscles, not regions. The risk is diffusion into the levator palpebrae superioris, the frontalis, the zygomaticus, the orbicularis oris or the deep neck — not proximity to a landmark.
Eyelid ptosis is the most common labeled reaction for glabellar lines, at 3% — not a rare event. Brow ptosis runs 2% when forehead lines are treated.
The label gives hard numbers: 1 cm above the supraorbital ridge, 1 cm above the central eyebrow, 2 cm above the eyebrow for the lower forehead row, 1 cm below the mandibular border in the neck.
Botox® carries a Boxed Warning for distant spread of toxin effect — and the same label states no definitive serious spread events have been reported at the labeled cosmetic doses.
The neck is the newest danger zone. Platysma bands became an FDA indication in October 2024, bringing dysphagia risk into aesthetic practice.
Filler danger zones and toxin danger zones are different maps. Filler risk is vascular; toxin risk is muscular. Confusing the two produces wrong advice.
What a “Danger Zone” Actually Means
The phrase gets used for two completely different problems, and mixing them up is the single most common error in consumer articles on this topic.
Filler danger zones are vascular. The concern is that hyaluronic acid enters an artery and blocks it, causing tissue death or, in the glabella and nose, vision loss. The safeguards are aspiration, cannulas, slow low-pressure injection and hyaluronidase on the shelf.
Botulinum toxin danger zones are muscular. Toxin is a protein solution injected in tiny volumes; it does not occlude arteries. The concern is chemical denervation of a muscle that was never the target. The safeguards are entirely different: depth, distance from bony landmarks, dose, dilution, needle orientation and an accurate read of that individual patient’s muscle anatomy.
The two maps overlap geographically — the glabella is dangerous for both — but a practitioner who treats them as the same subject will give the wrong advice about both. Everything below concerns toxin.
The Boxed Warning Every Injector Should Be Able to Explain
BOTOX® Cosmetic carries the FDA’s most serious class of warning, and it belongs in any honest discussion of danger. The label states that toxin effects may spread beyond the injection site to produce asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties, reported hours to weeks after injection, and that swallowing and breathing difficulties can be life threatening.
The sentence that almost never gets quoted alongside it is equally part of the label: no definitive serious adverse event reports of distant spread have been reported at the labeled cosmetic doses — 20 Units for glabellar lines, 24 for lateral canthal lines, 40 for forehead with glabellar lines, 44 or 64 Units for combined treatment, or 100 Units for axillary hyperhidrosis.
Both facts are true at once. The warning is real and applies to every botulinum toxin product on the market. The reassurance is that the risk concentrates in high-dose therapeutic use, in patients with underlying conditions that predispose them, and in treatment outside labeled doses. The practical instruction for patients is simple and non-negotiable: any difficulty swallowing, speaking or breathing after treatment warrants immediate medical attention.
The Glabella: Where Eyelid Ptosis Actually Comes From
The frown-line complex — two corrugator muscles and the procerus — sits directly above the orbital septum. Behind that septum runs the levator palpebrae superioris, the muscle that holds the upper eyelid open. Toxin placed too low, too deep or in too large a volume can track through the septum and weaken it. The result is true eyelid ptosis: a lid that sits visibly lower, sometimes low enough to obstruct vision, and that does not respond to willpower.
The label’s instructions for reducing this complication are specific and measurable:
Avoid injection near the levator palpebrae superioris, particularly in patients with larger brow depressor complexes
Place lateral corrugator injections at least 1 cm above the bony supraorbital ridge
Do not inject closer than 1 cm above the central eyebrow
Keep the injected volume and dose accurate and, where feasible, minimal
The labeled technique is 4 Units into each of 5 sites — two per corrugator, one in the procerus — for a total of 20 Units. In the clinical trials, eyelid ptosis occurred in 3% of treated subjects versus 0% on placebo, which makes it the most common adverse reaction for this indication. It is not a freak event, and a page that calls it rare is not preparing anyone.
The Forehead: The Brow-Ptosis Zone
The frontalis is the only muscle that lifts the brow. Relax too much of it, or relax its lower fibres, and the brow settles downward — a heavy, hooded look patients describe as feeling tired rather than frozen. This is brow ptosis, a different problem from eyelid ptosis, and it is the reason forehead Botox® dosing is treated as a planning exercise rather than a fixed recipe.
The label is unusually prescriptive here, because the safeguard is as much about strategy as placement:
Treat forehead lines in conjunction with glabellar lines — explicitly to minimize the potential for brow ptosis. Forehead lines are not a labeled stand-alone treatment.
Identify the superior margin of frontalis activity by palpation, roughly 1 cm above the most superior forehead crease
Place the lower treatment row midway between that margin and the eyebrow, and at least 2 cm above the eyebrow
Place lateral injections 0.5–1.5 cm medial to the palpated temporal fusion line (the temporal crest)
That last landmark is the label’s real answer to the “is the temple a danger zone?” question. The temporal fusion line is the boundary; injections belong medial to it. In the forehead-plus-glabellar trials, headache was reported in 9% of subjects, brow ptosis in 2%, eyelid ptosis in 2% and skin tightness in 2%.
Around the Eyes: Orbicularis Oculi, the Cornea and the Smile
Crow’s feet treatment targets the lateral orbicularis oculi, and it carries three distinct risks that have nothing to do with each other.
Going too medial or too deep
The label directs injectors to give injections with the needle bevel tip up and oriented away from the eye, and to place the first injection approximately 1.5–2.0 cm temporal to the lateral canthus and just temporal to the orbital rim. The labeled dose is 4 Units at 3 sites per side, 24 Units total. Eyelid edema was the most common reaction in these trials, at 1%.
Reduced blinking
The label carries two separate warnings for this region. Reduced blinking from injection in or near the orbicularis oculi can lead to corneal exposure, persistent epithelial defect and corneal ulceration — a particular concern in patients with seventh-nerve disorders. There is also a standalone dry eye warning, with instructions to refer to an ophthalmologist if symptoms persist.
Dropping too low
Below the crow’s feet sits the zygomaticus major, which lifts the corner of the mouth when you smile. Toxin that drifts inferiorly weakens it, and the patient ends up with an asymmetric or flattened smile on one side. Other toxin labels in this class specifically instruct injectors to avoid the zygomaticus major to prevent lip ptosis.
The Nose: What Actually Goes Wrong
The nose has a reputation as a danger zone that it partly borrows from filler. For toxin, the realistic complication is not breathing difficulty — that is Boxed Warning language about distant spread, and it does not describe what a nasalis injection does locally.
The realistic complication is a droopy lip or a crooked smile. When toxin placed for bunny lines at the nasalis migrates laterally or inferiorly, it reaches the levator labii superioris alaeque nasi (LLSAN) — the muscle running from the side of the nose to the upper lip. Weaken it and the upper lip on that side stops elevating properly. The patient sees it every time they smile, and it lasts as long as the toxin does.
Published anatomical guidance for the nasal region is consistent: injections should stay superficial, on the lateral nasal wall, high enough to stay clear of the LLSAN and the depressor septi nasi unless those muscles are themselves the deliberate target.
The Perioral Zone: Orbicularis Oris and the DAO
The muscles around the mouth do not just make expressions — they seal the lips for speech, drinking and eating. There is no compensating muscle to take over if the orbicularis oris is over-treated. The consequences patients report are unmistakable: difficulty pronouncing plosive sounds, inability to drink through a straw, food or liquid escaping the mouth, and a smile that no longer matches on both sides.
Doses here are a fraction of what the upper face tolerates, and the margin between effect and complication is small. The same applies to the depressor anguli oris (DAO), where the target muscle sits immediately beside the depressor labii inferioris. Place the injection a few millimetres off and instead of lifting a downturned mouth corner you have created a lower-lip asymmetry that shows whenever the patient speaks.
The Jawline and Neck: The Newest Danger Zone
BOTOX® Cosmetic received FDA approval for platysma bands in October 2024, which moved the neck from an off-label technique into labeled aesthetic practice — and brought a complication profile the upper face does not have.
The platysma is a thin sheet lying directly over the structures that manage swallowing. The label’s safeguards are explicit:
Administer injections at least 1 cm inferior to the lower mandibular border
Do not inject into structures deep to the platysma muscle, particularly in the anterior region of the neck
Have the patient contract the platysma to identify each band, then gently pinch the band to isolate the muscle from nearby anatomical structures during injection
Inject superficially and intramuscularly, needle perpendicular to the skin
The labeled regimen is 2 Units into each of 4 jawline sites per side plus 1 Unit into each of 5 sites per vertical band, totalling 26, 31 or 36 Units depending on how many bands are present. The related warning is that patients with smaller neck muscle mass have been reported to be at greater risk of dysphagia — which makes patient build, not just technique, part of the safety calculation in this zone.
What the Trial Data Actually Shows
Vague reassurance helps nobody. These are the reactions reported in at least 1% of BOTOX® Cosmetic treated subjects and more often than placebo, by treatment area, from the current prescribing information.
Lower row ≥2 cm above the eyebrow; treat with glabellar lines; stay medial to the temporal fusion line
Lateral canthal lines 24 Units, 6 sites
Zygomaticus major; orbicularis oculi (blink)
Eyelid edema 1%
Bevel up and away from the eye; 1.5–2.0 cm temporal to the lateral canthus
Platysma bands 26–36 Units
Deep neck structures (swallowing)
Profile consistent with other indications across 407 treated subjects
≥1 cm below the mandibular border; never deep to the platysma; pinch to isolate
Read across that table and a pattern appears: every labeled safeguard is a distance, a depth or a dose. None of them is a judgement call that experience alone supplies. What experience supplies is the ability to see, on one particular face, where those measurements actually fall — which is a different skill from knowing the numbers.
The Danger Zones That Are Not Anatomical
The wrong patient
Careful patient screening is part of the safety map, and the label defines it. BOTOX® Cosmetic is contraindicated in anyone with known hypersensitivity to a botulinum toxin preparation or its components, and in the presence of infection at the proposed injection site. The label also directs caution with pre-existing neuromuscular disorders, compromised respiratory function or swallowing difficulty, cardiovascular disease, and existing ptosis or muscle weakness at the site.
One more, easy to miss and consequential: units are not interchangeable between toxin brands. The label states plainly that BOTOX® Cosmetic units cannot be compared to or converted into units of any other botulinum toxin product. A “20 unit” conversion carried over from a different product is a dosing error, not a shortcut.
The wrong product
The most serious harm in recent years has come not from injection technique but from what was in the syringe and who was holding it. The CDC investigated a cluster of botulism-like illness traced to counterfeit or unverified-source botulinum toxin and to injectors who were not meeting state or local requirements. Some product had been bought through large online marketplaces rather than authorized suppliers; some was self-injected.
17CDC-investigated cases
9States affected
13Hospitalizations
18Websites warned by FDA, Nov 2025
In November 2025 the FDA issued warning letters to 18 websites illegally marketing unapproved and misbranded botulinum toxin, noting that product from unauthorized sources may be counterfeit, adulterated, contaminated, improperly stored or transported, ineffective or unsafe. No anatomical knowledge protects a patient from a vial that was never genuine. Asking who is injecting, what their license is, and where the product came from is as much a safety measure as any landmark in this article.
Why Expertise Matters for Botox® Injections
Every measurement in this guide is public. The label is free to download. What separates a safe injector from an unsafe one is not access to the numbers — it is the ability to locate them on a living, asymmetric, individual face, and to recognise when a patient’s anatomy means the standard pattern should be modified or the treatment declined.
A skilled injector palpates the frontalis at rest and at maximum elevation before choosing a row height. They assess brow position and levator function before touching the glabella. They ask the patient to contract the platysma before marking a band. They know which complications resolve on their own, which need referral, and how to have that conversation without losing the patient’s trust. Most of that is learned with a needle in hand, on real anatomy, under supervision — which is exactly what a structured complications curriculum and hands-on training are for.
Free Online Botox® Training · Earn 1 CME
Try Botox® training free. Earn 1 CME on us.
Get self-paced access to a real IAPAM Botox® module — watch step-by-step injection technique, follow along with our physician instructors, and claim 1 AMA PRA Category 1 CME when you finish.
Enter your details and we’ll email your access link.
Frequently Asked Questions
Where should Botox® never be injected?
There is no single forbidden spot. The FDA-labeled restrictions are anatomical: do not inject near the levator palpebrae superioris, do not inject closer than 1 cm above the central eyebrow, keep lateral corrugator injections at least 1 cm above the bony supraorbital ridge, keep the lower forehead row at least 2 cm above the eyebrow, and for platysma bands stay at least 1 cm below the lower mandibular border and never inject into structures deep to the platysma in the anterior neck.
What is the most common Botox® complication?
For glabellar lines it is eyelid ptosis, reported in 3% of treated subjects in the BOTOX® Cosmetic clinical trials versus 0% on placebo. For forehead lines treated with glabellar lines, the most common reactions were headache at 9% and brow ptosis at 2%. These are the labeled figures, not rare events.
Can Botox® cause breathing problems?
Breathing difficulty appears in the Boxed Warning as a symptom of distant spread of toxin effect, not as a local consequence of injecting any particular cosmetic area. The label states that no definitive serious adverse event reports of distant spread have been reported at the labeled cosmetic doses of 20, 24, 40, 44 or 64 Units. Any patient who develops trouble swallowing, speaking or breathing after treatment should seek immediate medical attention.
Are Botox® danger zones the same as filler danger zones?
No. Filler danger zones are vascular: the risk is that filler enters an artery and causes occlusion, tissue death or vision loss. Botulinum toxin danger zones are muscular: the risk is that toxin diffuses into a muscle you did not intend to treat, producing a droopy lid, a heavy brow or an uneven smile. The two maps overlap geographically but the mechanisms and the safeguards are completely different.
Is the neck a Botox® danger zone?
Yes, and it is the newest one. BOTOX® Cosmetic gained an FDA indication for platysma bands in October 2024. The label instructs injectors to administer at least 1 cm inferior to the lower mandibular border, to pinch each band to isolate the muscle, and not to inject into structures deep to the platysma, particularly in the anterior neck. The label also warns that patients with smaller neck muscle mass are at greater risk of dysphagia.
How do patients know their injector and their product are legitimate?
Ask who is injecting, what their license and training are, and where the product came from. The CDC investigated 17 cases across 9 states with 13 hospitalizations linked to counterfeit or unverified-source botulinum toxin and to injectors not meeting state requirements. In November 2025 the FDA issued warning letters to 18 websites illegally marketing unapproved botulinum toxin products. Legitimate product is bought through authorized distributors, not online marketplaces.
Training That Covers the Whole Map
Danger zones are not a list to memorise. They are the practical consequence of facial anatomy, and they are learned properly the same way anatomy always has been: on real faces, with an instructor beside you, before a paying patient is involved.
IAPAM’s hands-on Botox® training is built around exactly that — AMA PRA Category 1 CME, live models and product provided, taught by board-certified physician instructors in a clinical setting in Scottsdale, Arizona, with more than 20 years of training providers behind it. Practitioners learn the landmarks, then learn to find them on anatomy that never quite matches the diagram.
Disclaimer: This guide is for informational and educational purposes only and does not constitute medical advice. Treatment plans, injection techniques, and dosing must be tailored to each patient by a qualified, licensed provider. Always follow product labeling, your scope of practice, and your state medical and nursing board regulations.
Dr. Haley is a board-certified dermatologist with more than 20 years of experience in medical, cosmetic, and surgical dermatology. A former division head of academic dermatology at the National Naval Medical Center in Bethesda, she now trains licensed healthcare professionals in cosmetic injectables as an IAPAM clinical injection trainer.
Attend IAPAM’s comprehensive AMA PRA Category 1 CME BOTOX® training weekend and learn the clinical and business foundations for aesthetic practice growth.
✓Hands-on BOTOX® injection training in a clean, multi-million-dollar medspa—not a hotel.
✓Live models and product are provided so you can focus on learning with expert instructors.
✓Build foundations in five non-invasive treatments, with an optional GLP-1 weight-management business add-on.
